Background: Biological therapy is currently widely used to treat IBD. Infliximab,
| INTRODUCTION
The use of biologics is currently approved for moderate-to-severe Crohn's disease (CD) and moderate-to-severe ulcerative colitis (UC). [1] [2] [3] [4] [5] [6] [7] [8] [9] Infliximab, adalimumab and golimumab are antibodies to tumour necrosis factor-α (TNFα). These drugs work on a common pathway of blocking TNFα, a pro-inflammatory cytokine closely linked to acute phase reaction and systemic inflammation, thereby reducing the degree of damage to tissues. These have been devel- 
| AIMS AND METHODS
A MEDLINE and PubMed search was undertaken by (U.S, C.L) for articles pertaining to adverse effects of anti-TNF therapy in IBD.
After an initial title screen, all relevant articles were examined in full.
The main aim of the review is to focus on management of adverse events caused by anti-TNF therapy. For clarity, these AEs are discussed in categories as per systems, alongside recommended course of action including any further investigations or management. Where relevant, this manuscript also refers to international guidelines.
| Noninfectious complications and management strategies

| Hypersensitivity reactions
Hypersensitivity reactions vary widely in presentation, ranging from acute infusion reactions to delayed hypersensitivity. reactions can range from mild (flushing, dizziness, headache, itching, rash) to severe (anaphylactic-like). 2 Acute infusion reactions are relatively common, estimated to occur in up to 5% of infusions, with less than 1% of all infusions resulting in a severe reaction. 3 Patients with antibodies to infliximab are at an increased risk of infusion reactions 4 and case reports suggest hypersensitivity to adalimumab are also associated with adalimumab antibodies. 5 A review by the Food and Drug Administration (FDA) reported that injection site reactions were more common with adalimumab 6 with higher reporting odds ratio(ROR) in the 20-29 years age group (ROR = 16.18). The ROR was seen to reduce with increasing age. 6 Injection site reactions to golimumab in the PURSUIT study were low at 3.4% with no reported anaphylaxis or delayed hypersensitivity to 6 weeks. 7 Delayed reactions (24 hours to 14 days) presenting with arthralgia, myalgia, fever, fatigue and rash are much rarer (<1%). 3 The pathophysiology of immunological features are not completely understood. 8 
Management
The management of infusion reaction (IRs) is generally similar regardless of which agent has caused it. Typically, symptoms improve substantially or resolve completely after infusion rate adjustments and treatment with paracetamol, antihistamines or corticosteroids are provided. Evidence to support the use of premedication with corticosteroids or antihistamines is limited, with patients still experiencing infusion reactions despite premedication 9 and therefore should be considered on an individual basis. Injection site pain due to adalimumab can be reduced by using low volume formulations which are free from citrate buffers, with no change in efficacy. 10 In severe acute reactions, it is recommended that infusion is stopped and focus should be on maintaining airway, circulation as per standard anaphylaxis guidelines. 11 (Table 1 ) Delayed infusion reactions are typically managed by antihistamines, paracetamol and corticosteroids. A systematic review looked at management of infusion reactions and presented useful algorithms to manage mild, moderate and severe reactions. 12 These algorithms are simple, and a pragmatic tool to use for the vast majority of reactions seen in clinical practice. 12 After a hypersensitivity reaction, it is pragmatic to obtain therapeutic drug levels and anti-drug antibody levels.
| Haematological effects
Leucopenia
Neutropenia has been reported in anti-TNFα treatment-exposed patients, with up to 20% of patients developing neutropenia on at least one occasion. 13 TNFα up-regulates other proinflammatory cytokines, including interleukin-1 (IL-1), IL-6, IL-8, and granulocytemacrophage colony-stimulating factor, involved in the differentiation and maturation of haematopoietic progenitor cells. 14 TNFα blockade could mediate bone marrow failure by inhibiting stem cell differentiation. 15 However, the reduction in neutrophil count following TNFα inhibitor therapy is not seen for other cells from the same lineage (myeloid progenitor cell), specifically basophils, eosinophils and monocytes. The risk of neutropenia is significantly higher in patients
with a low baseline neutrophil count or a previous history of neutropenia.
13,16
Thrombocytopenia Isolated thrombocytopenia following the use of anti-TNF drugs 17, 18 has been reported. There are multiple hypotheses as to the possible aetiology, including autoimmune platelet destruction secondary to antiplatelet antibodies, immune complexes triggering the complement cascade, another unknown autoimmune mechanism, or idiosyncratic reaction.
18
Anaemia
Anaemia is considered a marker of active disease in IBD and therefore clinicians need to first consider this as an aetiology. The incidence and prevalence of anaemia was approximately 19% and 28%, respectively, in a recent population based cohort study. Crohn's with stricturing disease and long-standing UC were recognised as risk factors. 19 One study showed only marginal improvement in anaemia after treatment with anti-TNF therapy suggesting that disease activity in itself has a major role to play. 20 In this section, anaemia directly attributable to biologics is discussed, which is rare. There are sporadic case reports of aplastic anaemia with infliximab, more commonly in patients with rheumatoid arthritis than IBD. 21 A single case of infliximab induced autoimmune haemolytic anaemia (in a patient found to be anti-nuclear antibody (ANA) positive 1:40) has also been reported. 22 
Management of haematological effects
All patients starting anti-TNF therapy should have a baseline complete blood count with repeat testing every three to six months. At the onset of neutropenia, the anti-TNF should be withheld if the neutrophil count is deemed too low by the clinician. The patient should be left drug-free until neutrophil counts recover and anti-TNF therapy restarted when deemed clinically safe. Neutropenia can occur in patients managed with combination therapy with an antimetabolite and this should be borne in mind and should be discontinued first. A neutrophil count less than 1000 per mm 3 should raise concern and <500 per mm 3 should lead to discontinuation of incriminating drugs and close monitoring. Rare anti-TNF induced systemic lupus erythematosus should be excluded and sargramostim is rarely necessary after drug discontinuation.
Thrombocytopenia can be managed by drug cessation, corticosteroid therapy or rescue therapy with intravenous immunoglobulin (IVIG). Thrombocytopenia has been reported to be prolonged after cessation of therapy. In severe cases this could persist for up to 6 months and also preclude exposure to any further anti-TNF agents. 18 This is likely to be a class effect and rechallenge with same class could be risky and therefore discouraged. 17 In severe cases, specialist haematology input is suggested.
Anaemia in IBD is more commonly seen due to ongoing disease activity. Clinicians should first consider assessment for disease and strategies to control and manage anaemia secondary to disease as per guidelines. As anaemia related only to therapy is rare, there is no specific guidance in current literature regarding future therapy with anti-TNF. Cessation of therapy would depend on careful physicianpatient discussion taking into account the severity of anaemia and alternative treatment strategies. Involving haematologist in refractory cases would be prudent. (Table 2 ).
| Dermatological effects
In addition to skin malignancies anti-TNF therapy can cause a wide range of dermatological conditions. Most notably they include local skin irritation or reaction, increased skin infection rates, psoriasis, treat severe cases of psoriasis. Psoriasis is a relatively common side effect of anti-TNF therapy, with 1.5%-5% of patients developing this manifestation. 24 It is seen most commonly in females, typically 2-6 months following initiation of therapy. 25 A nation-wide cohort study reported incidence rates of anti-TNF induced psoriasis in IBD at 0.5% per patient-year. 26 A more recent study shows a much higher incidence at 10.5%, 27 but psoriasiform lesions are more common than psoriasis and have distinctive features. According to current evidence, females, smokers, and patients with fistulising disease appear to be at risk. 27 In addition to anti-TNF induced psoriasis, pso- 
Management
The management of autoimmune-like disorders/syndromes secondary to anti-TNF therapy requires a customised therapeutic approach according to severity of the induced autoimmune disease. ATIL should be considered a distinct condition and managed accordingly.
There are features which could help distinguish this. The incidence/ prevalence of dsDNA antibodies and hypocomplementaemia is greater in ATIL, whilst anti-histone antibodies, the hallmark of classic drug-induced lupus, are less commonly found. 32 In patients with a positive ANA, it is not in itself an indication for discontinuation of therapy. In the presence of mild features, cessation of anti-TNF therapy is probably sufficient. However, it can be continued in patients with isolated cutaneous lesions or immunological alterations in whom biologics are thought to be essential to treat underlying disease, with closer follow-up. In patients with involvement of internal organs (kidney, lungs, nervous system), cessation of therapy is mandatory with addition of corticosteroids and/or immunosuppressive agents. 30, 33 After discontinuation of the incriminating anti-TNF the prognosis is generally very favourable. The presence of diagnosed SLE is a contraindication to anti-TNF exposure.
| Cardiac effects
It was reported that worsening cardiac failure was a possible adverse event in a randomised controlled trial investigating the use of anti-TNF therapy in cardiac failure. 34 Majority of patients enrolled were
New York Heart Association III (NYHA) at baseline and the group receiving high dose infliximab (10 mg/kg) were adversely affected with an increased likelihood of hospitalisation, high frequency of worsening heart failure, with the risk of adverse clinical events persisting for up to five months after cessation of therapy. 34 The exact mechanism of heart failure with anti-TNF use remains unclear.
There have been case reports of second degree and complete heart block after infliximab therapy but these are rare. 35 This is more likely to happen in rheumatological conditions as there may be underlying cardiac involvement. A single blind prospective study which included rheumatological conditions concluded that new-onset cardiac arrhythmias, particularly ventricular tachyarrhythmia, developed during infliximab infusion, but their incidence did not achieve statistical significance. 36 Acute coronary syndrome following infusion has been reported but this too is very rare. 37 The rarer cardiac effects are based on reports with a very small number of patients, mostly from the rheumatology cohort who are at higher risk of having cardiac disorders.
Management
Current guidance recommends that use of anti-TNF therapy is best avoided in those with NYHA III/IV heart failure. 38 All patients who develop heart failure while on an anti-TNF agent should discontinue therapy, conventional medication for treatment of heart failure started and specialty advice sought. An alternate class of agent should be considered for the primary disease process. It is still unclear whether infliximab can be used safely in patients with asymptomatic left ventricular dysfunction or mild symptoms of heart failure (NYHA class I/II). 38 For patients commencing anti-TNF therapy who have specific cardiac risk factors such as hypertension, valve disorders or ischaemic heart disease, our recommendation is that clinicians should get a baseline electrocardiogram to record QT interval among other features and clinically assess the patient for any features of pre-existing heart failure that may preclude therapy. Not all studies have substantiated an association of anti-TNF therapy with heart failure and this is rare in patients with IBD (Table 4) .
| Neurological effects
Demyelination
Demyelination has been recognised as a complication of anti-TNF therapy. A review of FDA adverse event recording system showed that among 772 reports of neurological complications, 18% of patients had IBD. About 36% of patients had received infliximab and peripheral neuropathy was the most commonly reported event. 39 Demyelination can occur in central or peripheral nervous systems. 40 It remains unclear as to whether the relationship is truly causal, or whether anti-TNF triggers an existing tendency for demyelination.
Management
Patients who have a family history of demyelination disorders may be at higher risk and this should be considered before the therapeutic agent is chosen. 41 It is standard guidance to avoid anti-TNF therapy in patients with concomitant multiple sclerosis or history of optic neuritis. In patients who develop neurological deterioration and suspected demyelination during therapy, treatment with biologic agent should be discontinued 41 and specialist neurology opinion should be sought. The clear relationship between demyelinating events and anti-TNF can be difficult to establish as IBD may also be associated with demyelination. Treatment with corticosteroids, IVIG, and plasmapheresis are rarely necessary (Table 5 ).
| Infections and management strategies
Biologics are strong immunosuppressive agents and can increase risk of infection depending on their mechanism of action. Tumour necrosis factor-α (TNFα) is essential for activation, differentiation, and recruitment of several immunological cell types; it has a role in granuloma formation, maintenance of granuloma integrity, 42 and host response to mycobacteria and intracellular organisms. 43 A recent meta-analysis found that anti-TNF therapy was associated with a greater infection risk than placebo in treating UC but anti-integrin therapy was not; neither class showed an increased infection risk over placebo in CD. 44 Other studies have confirmed increased risk in both forms of IBD.
A recent systematic review by Wheat et al concluded that at present there is no evidence of a higher odds of serious infection from the newly available biologic therapies such as vedolizumab and ustekinumab compared to anti-TNFs. 45 Feagan et al report that infections in patients exposed to ustekinumab for CD is no higher than placebo in UNITI trials 46 and Wils et al reported only one serious pulmonary infection in a cohort of 122 ustekinumab exposed patients, followed up over 2 years. 47 Bye et al reported an increased risk of Clostridium difficile infection with vedolizumab therapy but concomitant steroid and narcotic analgesics were identified as risk factors. 48 
| Bacterial infections
Patients receiving anti-TNF therapy have been reported to acquire both common and uncommon bacterial infections. Restarting therapy can be considered once patients are afebrile, white cell counts within normal range and relevant imaging (CT, MRI pelvis) show no evidence of infective source. (Table 6 ).
| Uncommon infections
Several nonmycobacterial intracellular infections, including listeriosis caused by Listeria monocytogenes and legionnaires' disease most often caused by Legionella pneumophilia, have been associated with anti-TNF therapy. 50 Listeria sepsis and meningitis have been described in patients receiving anti-TNF drugs 51 and in 2011, the FDA added a boxed warning about the risk of listeriosis and legionnaires' disease for the entire class of TNFα inhibitors. 52 There are a few case reports of listeriosis complicating anti-TNF therapy. Listeriosis carries significant mortality, therefore requiring prompt diagnosis and aggressive treatment. The risk appears to be higher during the first year of therapy. 53 Anti-TNF should be discontinued till the patient recovers from listeriosis.
| Management
Suspicion of infection requires confirmatory testing and treatment using standard antibiotic regimes depending on pathogen isolated.
Listeriosis is more likely to be seen in patients consuming mouldripened cheese regardless of whether it is from pasteurised or unpasteurised milk and also from cold smoked gravad fish. 54 In one study from United States, unpasteurised milk and dairy products were noted to significantly increase the risk of infections caused by Escherichia coli, Salmonella, and Campylobacter. 55 In view of this overall increased risk of infections, it is safer for patients to avoid consumption of unpasteurised milk whilst on anti-TNF drugs.
| Mycobacteria and tuberculosis
Tuberculosis (TB) caused by mycobacterium bacilli is a serious infection which carries significant morbidity. TNFα is necessary for a Th1-based cell-mediated immune response important in activating macrophages to kill intracellular mycobacteria, and limit spread by formation of granulomas. 56, 57 The majority of exposed immunocompetent hosts have latent TB (LTB) which can subsequently lead to reactivation of infection if there is compromise to the immune system, such as initiation of anti-TNF drugs. 58 It is therefore critical to identify and treat LTB prior to starting anti-TNF therapy. 58 An association between anti-TNF therapy and development of 
| Management
Guidelines by European Crohn's and Colitis organisation (ECCO) 26 and British Thoracic Society (BTS) 58 on screening and management of TB are similar in principle, suggesting treatment of LTB prior to initiation of anti-TNF therapy with a complete therapeutic regimen.
If there is clinical suspicion ± radiographic changes suggestive of TB, patients should be referred for treatment of LTB. 58 Other patients should undergo LTB screening tests. The optimal screening strategy for these patients is still debatable.
After diagnosis of latent TB in a patient with IBD, appropriate treatment should be administered for at least 3 weeks prior to commencement of anti-TNF therapy 64, 65 ; however, if treatment with There are viruses linked to malignancy, such as Epstein-Barr virus (EBV) and human papilloma virus (HPV). EBV will be discussed in more detail in "malignancy" section of this text.
| Varicella zoster virus (VZV) and Shingles
This can present with severe or disseminated disease if contracted while on anti-TNF therapy. 68 In one study, the prevalence of prior varicella zoster virus (VZV) infection among IBD patients was greater than 90% 69 and it was not noted that a significant number had a VZV IgG negative status. It is known that patients with IBD are at a higher risk of VZV infection and more so when on immunosuppressive therapy. 70, 71 Herpes zoster or shingles is caused by reactivation of VZV. The incidence of shingles is again increased in patients with IBD, the elderly population at particular risk. In a study looking at herpes zoster in IBD, it was seen that patients with CD were at higher risk;
age >45 years, treatment with corticosteroids for >2 weeks, thiopurine therapy were associated with increased risk of infection. 72 Long et al reported similar findings and also noted that patients on anti-TNF therapy for IBD are at higher risk of herpes zoster with an odds ratio of 1.81 (95% CI: 1.48-2.21). 
| Management
Immunocompromised patients exposed to VZV should be treated with VZV immunoglobulin. 74 Patients who contract VZV or shingles during a period of immunosuppression require antiviral therapy. If oral therapy is appropriate, valganciclovir should be considered as this provides higher oral bioavailability than aciclovir. 65 (Table 7) Prevention of infection is possible due to availability of effective vaccines. It is recommended that all patients are screened for evidence of past infection prior to starting biologics or immunosuppressives including steroids. ECCO suggest that in seronegative patients two-dose course of varicella vaccine should be given at least 3 weeks prior to commencement of therapy. 65 If subsequent immunisation is necessary, it can be administered after a 3-6 month cessation of all immunosuppressives as both the VZV and shingles vaccines are live vaccines, 65 although there is emerging evidence that administration of live zoster vaccine to patients already on anti-
TNF therapy did not result in disease and there was expected immune response to the vaccine. should be done. 65 Chronic HBV carriers and those with HbsAg seroconversion should be considered for antiviral therapy and hepatology involvement. It is recommended that patients who are due to start biologics (moderate risk of reactivation) are given anti-viral prophylaxis if they are HBsAg positive and continued for at least 6 months after completion of immunosuppressive therapy. 80 In case of reactivation, it is recommended that one of the antivirals is started and continued for at least 6-12 months after immunosuppressive therapy has been stopped. The antiviral medication of choice may depend on the patient's individual circumstances and the planned duration of immunosupression. 81 Entecavir and tenofovir are now preferred antivirals in IBD patients due to their rapid onset of action, highest antiviral potency with low incidence of resistance. 65 Whilst lamivudine is used, this has its limitations if long term therapy is required, as resistance can occur in up to 30% of patients after 1 year and 70% after 5 years. 81 Peginterferon-alpha-2a (IFNα) is best avoided due to the risk of myelosuppression and also risk of exacerbating CD. 
| Hepatitis C
Tumour necrosis factor-α (TNFα) appears to be involved in the pathogenesis of HCV, with patients with higher serum TNFα levels less likely to respond to anti-viral therapy. 82 TNFα blockade may In the presence of chronic HCV, the decision to treat with anti-TNF depends on liver synthetic function. It is best avoided in patients who are Child-Pugh category B or C. 83 HCV patients being treated
with anti-TNF therapy should have close monitoring of aminotransferases with consideration for discontinuation of treatment with continued elevations. 82 The guidelines from ECCO suggest cautious use of antivirals due to drug interactions. 65 Infection diagnosed whilst on anti-TNF therapy does not necessarily require cessation of therapy. 65 There is no data yet on the use of newer antivirals for HCV in the context of biologics use for IBD but there are no contraindications for their concurrent use.
| Management
The ECCO guidelines are equivocal about screening for HCV prior to use of immunosuppressive therapy. 65 However, it would be prudent to screen patients who are likely to need biologics considering the high curative rates with newer anti-viral drugs for HCV. All patients with HCV infection should be discussed and managed jointly with hepatology services, especially when biologics are indicated for IBD. During the course of therapy, close monitoring of liver functions is key.
| HIV infection
The interaction between TNFα and the human immunodeficiency virus (HIV) has been the subject of much scrutiny. The molecular pathway by which HIV expression is upregulated by TNFα is well described. 84, 85 Despite these findings, use of anti-TNF in HIV-patients must be balanced with a potential increase in the risk of opportunistic infections in patients with an attenuated immune system.
The evidence base for advice regarding use of biologics in patients with HIV and IBD is limited. Within a cohort study and several case reports, biologic therapy with infliximab in refractory IBD patients has been demonstrated to be effective in inducing disease remission with only a minority experiencing adverse effects. [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] It is important to note that initial CD4+ count in patients included in these studies are >200 cells/mL. The ECCO guidelines 65 (Table 7) 
| Fungal infections
Patients with IBD are known to be at an increased risk of fungal infections. This is due to multiple factors such as severity of disease activity, comorbidities, treatment with opioids, surgery, poor nutritional status, leucopenia and older age. 91 Another factor is immunosuppressive therapy, important of which are anti-TNFs. A risk factor analysis by one recent systematic review reported anti-TNF therapy as the predominant factor associated with fungal infections. it is involved in polymorphonuclear leucocyte activation in response to infection. 92 The evidence is mostly from case reports. In 2001, a case of invasive pulmonary aspergillosis was reported in a patient with CD on anti-TNF therapy. 93 There have been other case reports since but overall, it appears to be a rare occurrence. This usually presents initially with a poorly productive cough and can progress to respiratory insufficiency; radiological changes are seen.
93,94
| Management
The definitive diagnosis is on culture of broncho-alveolar fluid. The infection is treated with prolonged antifungal therapy based on SHIVAJI ET AL.
| 673 sensitivities; amphotericin B or voriconazole or caspofungin is used.
The condition carries very poor prognosis. Concomitant tuberculous cavity needs exclusion (Table 8 ).
| Histoplasmosis
This is another potential opportunistic infection reported in patients exposed to anti-TNF treatment. In a case series of ten immunocompromised subjects from an area endemic with histoplasmosis, 9 contracted histoplasmosis shortly after commencing infliximab infusions.
Clinical presentation can be varied and include pulmonary, extrapulmonary or disseminated disease symptoms which are nonspecific. the management of such cases (Table 8 ).
| Other Opportunistic infections
| Cytomegalovirus (CMV)
Cytomegalovirus (CMV) infection (detected by serology) could be due to reactivation of latent infection during immunomodulator or biologic therapy, but usually is itself mild or asymptomatic even on immunosuppressants. However, CMV colitis, retinitis, pneumonia or severe CMV infection during treatment of IBD requires further assessment 65 to plan management. Nevertheless, not all cases of CMV infection in anti-TNF use progress to CMV disease. 97 The diagnosis of CMV disease using histopathology with immunohistochemistry is highly sensitive and specific. This combined with CMV viral load (CMV DNA detected by PCR in serum and tissues) can provide most information about disease state. 65 CMV viral loads of >250 copies/mg is a predictor for patients presenting with corticosteroid-resistant disease. 65 Cytomegalovirus disease manifesting as colitis is a recognised complication of IBD and should be screened for in those patients presenting with acute severe colitis. 98 Typically, patients may have had previous exposure to immunosuppressive therapy and experienced prolonged corticosteroid therapy or corticosteroid-refractory disease. CMV can also be a cause of chronic pouchitis. 
| Management
It is important that diagnosis is established swiftly. When considered as a differential diagnosis, testing for CMV viral load with PCR is recommended to look for CMV disease especially in ill patients with systemic manifestations. Histology and immunohistochemistry may be used to support the diagnosis of CMV colitis. Once diagnosed, ECCO recommend a 2-3 week course of ganciclovir therapy for CMV disease, and immunosuppressants are withheld. 65 However, a retrospective cohort case study of CMV-positive colitides, identified that patients with milder colitis were less likely to be treated, and could respond to standard immunosuppressive therapy without additional treatment for CMV. CMV may be transiently reactivated and disappear without antiviral therapy. In one study it was noted that those with more severe disease were more likely to be treated with ganciclovir, and were more likely to require either rescue therapy or (Table 7) .
| Pneumocystis pneumonia (PCP) or
Pneumocystis jirovecci pneumonia (PJP)
This is a serious infection reported in patients after use of immunosuppressants. A large population based cohort study looked at risk of PJP in IBD patients. 103 Although there is some evidence that the overall hazard risk of PJP in IBD is higher than normal population, the absolute risk of PJP is considered to be very low (0.03% in their cohort). 103 In a large case series of PJP after infliximab use, mean onset of symptoms reported was 21 days although majority of patients were exposed to concomitant immunosuppressive therapy. Over a quarter (27%) of patients died 104 in these reported series, so early recognition and therapy is paramount.
ECCO guidance recommends that patients on triple immunotherapy with one being a calcineurin inhibitor or anti-TNF should receive standard prophylaxis with Trimethoprim-sulfamethoxazole (co-trimoxazole) if tolerated. It should be considered in those on dual immunosuppression especially if one is a calcineurin inhibitor 65 and in anti-TNF regimens with associated corticosteroid use. 65 However, pill-burden and side effects are to be kept in mind. Cotrimoxazole is an effective option for prophylaxis and active infection. Clinicians should discuss with their local microbiology and infectious disease departments. Although more recent studies report very low risk, clinicians have to be vigilant throughout the course of treatment and decision on prophylaxis has to be on a case-by-case basis (Table 8 ).
| Infection prevention and vaccination recommendations
The main focus of the article is on management of adverse effects and our stress on prevention, though very important, is limited as Historically most trial data are from the rheumatology population.
A meta-analysis derived from nine clinical trials of patients receiving anti-TNF treatment or placebo identified a number needed to harm of 154 (95% CI: 91-500) for 1 additional malignancy within a treatment period of 6-12 months. 108 The malignancy rates were signifi- or combination therapy to be an independent risk factor for malignancy. 112 However, the follow-up period remains short and future analysis of the registry is likely to provide further evidence.
The CESAME Study Group 113 assessed the impact of thiopurine use on development of NMSC-comprised of basal cell carcinoma, squamous cell carcinoma, and lymphoproliferative disorders (increased risk found in the thiopurine group). Although a large number of patients were included, the risk of malignancy secondary to biologics could not be assessed due to relatively small number of patients on these drugs. 114 115 Another study in 2012 reported that patients were at higher risk of melanoma when exposed to biologics and NMSCs were mainly related to thiopurine therapy. 116 The most recent French national cohort study showed an increased risk of lymphoma in treatment exposed patients. When compared with unexposed patients, the risk of lymphoma was higher among those exposed to thiopurine monotherapy (aHR, 2.60; 95% CI: 1.96-3.44; P < 0.001), anti-TNF monotherapy (aHR, 2.41; 95% CI: 1.60-3.64; P < 0.001), or combination therapy (aHR, 6.11; 95% CI: 3.46-10.8; P < 0.001).
117
There remains concern about cases of hepatosplenic T-cell lymphoma (HSTCL) (a rare and aggressive form of non-Hodgkin's lymphoma affecting predominantly young men) occurring following infliximab, adalimumab or thiopurine use. In a study published by
Thai et al, they reported 22 cases of HSTCL in IBD and most were associated with thiopurine therapy either as monotherapy or in combination with anti-TNF. Whilst a link is recognised, quantifying this risk to individual patients on current evidence is difficult. 118 They also concluded that despite the risk, benefits of treatment far outweighed the risks. 118 Secondly, observational studies have noted a potential predisposition to development of EBV related lymphoproliferative disorders in IBD patients, in particular those treated with thiopurines and anti-TNF agents. 65 Patients with EBV are predisposed to post-transplant lymphoproliferative disorders (PTLD), where T-cell immune surveillance is impaired. 65 EBV related lymphomas may present in the gut, rather than nodal sites. Screening for EBV should ideally be considered, however there is no current vaccination for EBV naïve patients. In those developing EBV on therapy, treatment with antiviral medication and withdrawal of therapy should be considered. 65 IBD itself does not appear to increase risk of lymphoma diagnosis. 119 However, use of a thiopurine for IBD or combination therapy with an anti-TNF may increase risk. 119 Establishing any isolated effect of anti-TNF on lymphoma development is challenging. In a meta-analysis looking at lymphoma rates in CD patients treated with anti-TNF, two thirds of all patients were also receiving immunomodulator therapies 120 ; anti-TNF treated patients appeared to have an increased risk of lymphoma (SIR 3.23 95% CI: 1.5-6.9) compared to the expected population rate. 120 The SIR was also increased when compared to previously studied patients on immunomodulator therapy alone (1.7 95% CI: 0.5-7.1), however this did not reach statistical significance. 120 There were too few patients treated with isolated anti-TNF therapy to determine the individual risk of anti-TNF usage on lymphoma development. rence. 121 In a meta-analysis of 16 studies of immune mediated diseases, including eight studies involving IBD patients, similar rates of cancer recurrence were observed among individuals affected by previous cancer who received no immunosuppressives, anti-TNF monotherapy, immunosuppressant therapy or combination therapies. 122 Therefore, in patients with a history of cancer, recent or past, effective therapy for IBD can be used after consideration of risks and benefits and discussion with oncologists. ECCO guidelines also provide advice on managing IBD patients with previous history of malignancy. 123 Generally, among biologics, monotherapy anti-TNF, vedolizumab, or ustekinumab may all be used, but often thiopurines are avoided (Table 9) .
| CONCLUSION
The use of biologics is now a standard therapy for IBD used either 
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